1. A method of treating type 2 diabetes mellitus in a subject in need of treatment, comprising: providing continuous delivery of an incretin mimetic from an osmotic delivery device, wherein a significant stable delivery of incretin mimetic in a therapeutic concentration is achieved for a period of time of about 7 days or less after implanting said osmotic delivery device to a subject, and said substantial stable delivery of incretin mimetic from the osmotic delivery device is discontinuous during administration period of at least about 3 mesyatsa.2. A method according to claim 1, characterized in that a substantial stable delivery of incretin mimetic in therapeutic concentrations is achieved after implantation of an osmotic delivery device to a subject for a period of time selected from the group consisting of about 5 days or less, about 4 days or less, about 3 days or less, about 2 days or less, about 1 day or less. 3. A method according to claim 1, characterized in that the substantial stable delivery of the incretin mimetic from the osmotic delivery device is continuous during the administration period selected from the group consisting of periods from at least about 3 months to about one year, from at least about 4 months to about one year, from at least about 5 months to about one year, from at least about 6 months to about one year, from at least about 8 months to about one year, and from at least m Here about 9 months to about one year. 4. The method according to claim 1, additional1. Способ лечения сахарного диабета 2 типа у субъекта, нуждающегося в лечении, включающий:обеспечение непрерывной доставки миметика инкретина из осмотического устройства доставки, при этом существенная стабильная доставка миметика инкретина в терапевтической концентрации достигается в течение периода времени, составляющего примерно 7 дней или менее после имплантации указанного осмотического устройства доставки субъекту, и указанная существенная стабильная доставка миметика инкретин
